SSR2 and meningioma: In a phase II single-center study, Gerster-Gilliéron’s group [37] investigated response, survival and safety of PRRT in a cohort of 15 subjects with recurrent or progressive meningiomas, positive for SSR2 expression at 111In-pentetreotide scintigraphy, submitted to 90Y-DOTATOC with a dose fixed at 3700 MBq/m2 twice, with an 8-week interval.